<code id='4723FC21DE'></code><style id='4723FC21DE'></style>
    • <acronym id='4723FC21DE'></acronym>
      <center id='4723FC21DE'><center id='4723FC21DE'><tfoot id='4723FC21DE'></tfoot></center><abbr id='4723FC21DE'><dir id='4723FC21DE'><tfoot id='4723FC21DE'></tfoot><noframes id='4723FC21DE'>

    • <optgroup id='4723FC21DE'><strike id='4723FC21DE'><sup id='4723FC21DE'></sup></strike><code id='4723FC21DE'></code></optgroup>
        1. <b id='4723FC21DE'><label id='4723FC21DE'><select id='4723FC21DE'><dt id='4723FC21DE'><span id='4723FC21DE'></span></dt></select></label></b><u id='4723FC21DE'></u>
          <i id='4723FC21DE'><strike id='4723FC21DE'><tt id='4723FC21DE'><pre id='4723FC21DE'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:122
          ASH19 CAR-T
          Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

          The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

          That sounds staggering to many patients — but it’s far less than analysts expected.

          advertisement

          The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Sudafed saga points to U.S. issues with evaluating older drugs
          Sudafed saga points to U.S. issues with evaluating older drugs

          PATRICKT.FALLON/AFPviaGettyImagesYouwouldhavebeenforgivenforbeingsurprisedonSept.12whenapanelofadvis

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Eli Lilly expects to double planned employment in Boston center

          Anartist'srenderingofthebuilding—currentlyunderconstructionalongBoston'sFortPointChannel—whereEliLil